Welcome from the ISCP President

 

Welcome to the website of the International Society of Cardiovascular Pharmacotherapy (ISCP). ISCP is a Global organization, affiliated to the World Heart Federation, whose mission is to promote and facilitate strategies to improve cardiovascular health through rational pharmacotherapy.

ISCP represents a forum for dialogue and cooperation among cardiac physicians, pharmacologists, pharmacists, scientists with an interest in cardiovascular pharmacology, and health care professionals in general.

We are a global organisation with a large membership from over 35 countries worldwide. Most countries have an ISCP Governor and through them we encourage local participation in events and collaboration in projects and strategies to improve cardiovascular health through the promotion of education and research in all areas of cardiovascular pharmacotherapy. The ultimate goal always being the prevention of cardiac disease and the improvement of treatment, clinical outcome and patient wellbeing.

The ISCP promotes cooperation among societies with interests in CV pharmacotherapy and allied/related disciplines worldwide, sponsors international and regional meetings on CV pharmacotherapy and offers logistic support to scientists wishing to carry out short visits to leading institutions worldwide.

The Society endeavours to stimulate ethical -nondiscriminatory- research programs, educational activities and pharmacological treatments worldwide. ISCP strongly supports the notion of equal opportunities for individuals of all races and gender, religions, ethnic origins, citizenship, political philosophies or sexual orientation. Full or website-only membership to the ISCP can be applied for on-line.

I truly hope you will join us and participate in our educational and research endeavours and I especially hope that many of you will be able to join us in Barcelona in August for what we are sure will be an inspiring and memorable 22nd Scientific Meeting of the Society.

Antoni Martinez-Rubio, President
ISCP

 

ISCP Mission Statement

The mission of the International Society of Cardiovascular Pharmacotherapy (ISCP) is to promote and facilitate strategies to improve cardiovascular health through cooperation among cardiac physicians and surgeons, pharmacologists, pharmacists, scientists, and medical practitioners worldwide.
ISCP promotes education, research and evidence-based clinical management in all areas of cardiovascular pharmacotherapy with the ultimate goal of prevention and improving treatment, outcome and patient wellbeing.

ISCP
1. Promotes cooperation among individuals, organizations and societies with an interest in CV pharmacotherapy and allied/related disciplines worldwide.
2. Sponsors international and regional meetings on CV pharmacotherapy.
3. Encourages collaboration among scientists, physicians, surgeons, nurses and health care professionals with an interest in cardiovascular pharmacotherapy. It offers logistic support to scientists wishing to carry out short visits to other institutions with the aim of learning techniques, training on specific pharmacotherapy topics and exchanging research and management ideas.
4. Endeavours to stimulate ethical -nondiscriminatory- research programmes, educational activities and pharmacological treatments worldwide. ISCP strongly supports the notion of equal opportunities for individuals of all races and gender, religions, ethnic origins, citizenship, political philosophies or sexual orientation
5. Facilitates interactions among cardiovascular physicians, surgeons, pharmacologists and scientists working on related fields under the umbrella of the World Heart Federation and other international bodies such as WHO and UNESCO.
6. Promotes the development of novel CV pharmacotherapy techniques and protocols.
7. Endorses and develops programmes aimed at increasing public awareness regarding pharmacological treatment issues worldwide, with especial emphasis on issues specific to developing countries.
8. Strives to lead on CV pharmacotherapy education at all levels.
9. Is committed to endorse research and educational programmes leading to high quality patient care.
10. Supports the development of evidence-based, ethical, treatment guidelines which contemplate the specific needs of different regions in the world.